StreetInsider.com News Articles

NeurAxis Announces Medical Policy Coverage Milestone, Expanding Access to 26 Million Additional Covered Lives

Thu, 15 Oct 2026 09:18:00 -0400

CARMEL, Ind., Oct. 15, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and adults, today announced significant new medical policy coverage from a major national health insurer for Percutaneous Electrical Nerve Field Stimulation (“PENFS”). The coverage spans multiple states and represents approximately 26 million medical plan members.

NeurAxis’ proprietary PENFS technology, IB-Stim, is FDA-cleared for the treatment of functional abdominal pain associated with irritable bowel syndrome (IBS) and Functional Dyspepsia (FD) including associated nausea symptoms in

NeurAxis Announces Medical Policy Coverage Milestone, Expanding Access to 26 Million Additional Covered Lives

Thu, 15 Oct 2026 09:18:00 -0400

Form 8-K Neuraxis, INC For: Oct 14

Wed, 14 Oct 2026 17:00:00 -0400

si-local-file:///var/storage/secattach/20261014/27187774.html

Form 4 Neuraxis, INC For: Oct 08 Filed by: Carrico Brian Allen

Thu, 08 Oct 2026 17:50:00 -0400

si-local-file:///var/storage/secattach/20261008/27167830.html

Form 4 Neuraxis, INC For: Oct 08 Filed by: Carrico Thomas Joeseph

Thu, 08 Oct 2026 17:48:00 -0400

si-local-file:///var/storage/secattach/20261008/27167824.html

Form 4 Neuraxis, INC For: Oct 08 Filed by: Henrichs Timothy Robert

Thu, 08 Oct 2026 17:46:00 -0400

si-local-file:///var/storage/secattach/20261008/27167820.html

Form 3 Neuraxis, INC For: Sep 28 Filed by: Blanchard Craig Thomas

Tue, 29 Sep 2026 09:00:00 -0400

si-local-file:///var/storage/secattach/20260929/27118495.html

NeurAxis names Craig Blanchard as chief commercial officer

Tue, 29 Sep 2026 07:00:48 -0400

NeurAxis, Inc. (NYSE American: NRXS) has appointed Craig Blanchard as Chief Commercial Officer, the medical technology company announced. In the role, Blanchard will oversee sales and marketing functions at the Carmel, Ind.-based company.

Blanchard previously served as Vice President of Product Strategy, Marketing and Field Clinical at NICO Corporation, where he led commercial strategy for minimally invasive neurosurgery technologies. NICO was acquired by Stryker in 2024, with its technologies having reached more than 40,000 patients. Earlier in his career, Blanchard held commercial leadership positions at Boston Scientific and Guidant Corporation.

"Craig joins NeurAxis at an important inflection point in our commercial growth,"

NeurAxis Positions for Next Phase of Commercial Growth with Appointment of Craig Blanchard as Chief Commercial Officer

Tue, 29 Sep 2026 07:00:00 -0400

CARMEL, Ind., Sept. 29, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and adults, today announced the appointment of Craig Blanchard as Chief Commercial Officer. In this role, Mr. Blanchard will oversee the Company’s commercial functions, including sales and marketing.

The appointment of Mr. Blanchard as Chief Commercial Officer represents a strategic investment in the significant growth opportunity NeurAxis sees ahead. With the Company expecting to expand its commercial organization alongside a substantial increase in covered

NeurAxis Positions for Next Phase of Commercial Growth with Appointment of Craig Blanchard as Chief Commercial Officer

Tue, 29 Sep 2026 07:00:00 -0400

NeurAxis gains coverage for IB-Stim device covering 18M new members

Wed, 16 Sep 2026 09:02:48 -0400

NeurAxis, Inc. (NYSE American: NRXS) announced that a major national health insurer has established a medical policy covering its Percutaneous Electrical Nerve Field Stimulation technology, known as IB-Stim, adding approximately 18 million health plan members across multiple states to its covered population.

IB-Stim is FDA-cleared for the treatment of functional abdominal pain associated with irritable bowel syndrome and functional dyspepsia, including associated nausea symptoms, in patients aged 8 and older. The device stimulates cranial nerve bundles in the ear to regulate pain signaling between the gut and the brain.

According to the company, no FDA-approved drug therapies currently exist for pediatric patients

NeurAxis Announces Medical Coverage Policy Milestone, Expanding Access to Over 18 million additional Covered Lives

Wed, 16 Sep 2026 09:00:00 -0400

CARMEL, Ind., Sept. 16, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and adults, today announced significant new medical policy coverage from a major national health insurer for Percutaneous Electrical Nerve Field Stimulation (“PENFS”). The coverage spans multiple states and represents approximately 18 million health plan members.

NeurAxis Announces Medical Coverage Policy Milestone, Expanding Access to Over 18 million additional Covered Lives

Wed, 16 Sep 2026 09:00:00 -0400

NeurAxis to Participate in the Lytham Partners Fall 2026 Investor Conference

Wed, 16 Sep 2026 07:00:00 -0400

CARMEL, Ind., Sept. 16, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. ("NeurAxis," or the "Company") (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and adults, will participate in a webcast presentation and host one-on-one meetings with investors at the Lytham Partners Fall 2026 Investor Conference, taking place virtually on September 29-30, 2026.

Company Webcast

The webcast presentation will take place at 11:45 a.m. ET on Tuesday, September 29, 2026. The webcast can be accessed by visiting the conference website at https://lythampartners.com/fall2026/ or directly

NeurAxis to Participate in the Lytham Partners Fall 2026 Investor Conference

Wed, 16 Sep 2026 07:00:00 -0400

Company Webcast

Form 4 Neuraxis, INC For: Aug 24 Filed by: Carrico Brian Allen